AstraZeneca coronavirus vaccine registered 74 per cent efficacy at stopping vital diseases, according to the company’s US clinical trial results. The data was tested on over 26,000 volunteers in the US, Chile and Peru, who got two shots of the Covid-19 vaccine. The results were published in the New England Journal of Medicine.

• BharatPe Launched All-In-One Payment Product – BharatPe One
• KP Energy Shares Locked at 5% Upper Circuit On Securing New Order and Release of Financials
• RIL Becomes First Indian Company To Cross Rs 100,000 crore Threshold Pre-tax Profits, Shares Traded Flat
• Shish Industries Shares Skyrocketed 20% on Receiving Order Worth Rs 312 Crore
• Hatsun Agro Shares Gained 14% on Robust Q4FY24 Business and Financial Updates

“I was stunned,” Dr Anna Durbin, a vaccine researcher at Johns Hopkins University and one of the investigators, said of the overall result. “It was also very protective against serious disease and hospitalisation,” she said. AstraZeneca has said in July that it is planning to file full approval with the US Food and Drug Administration (FDA) rather than ask for emergency use authorisation. The company is also examining booster doses for people who have already been fully vaccinated.